A Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Virus Vector for Cancer Therapy
Description of Invention:
Tumor-selective, replicating viruses may infect and kill cancer cells and efficiently express therapeutic genes in cancer cells. The current invention embodies mutant vaccinia virus expression vectors. These vectors, which are vaccinia virus growth factor-deleted and thymidine-kinase deleted, are substantially incapable of replicating in non-dividing cells, and as such have specificity for cancer cells. It is therefore believed that the vectors will be of value for cancer therapy either by directly killing cancer cells or by expressing therapeutic agents in cancer cells while sparing normal, non-dividing cells.
Inventors:
J. Andrea McCart (NCI) David L. Bartlett (NCI) and Bernard Moss (NIAID)
Patent Status:
DHHS Reference No. E-181-1999/0 --
U.S. Patent Application No. 09/991,721 filed 13 Nov 2001, claiming priority to 28 May 1999
Relevant Publication:
E. Chang et al., "Targeting vaccinia to solid tumors with local hyperthermia," Hum Gene Ther. 2005 Apr, 16(4):435-44.
J.A. McCart, "Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide," Mol Ther. 2004 Sep, 10(3):553-61.
H.J. Zeh, "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers," Cancer Gene Ther. 2002 Dec, 9(12):1001-12.
J.A. McCart, "Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes," Cancer Res. 2001 Dec 15, 61(24):8751-7.
Portfolios: Cancer
Cancer -Therapeutics-Gene Therapy-Vectors Cancer -Therapeutics
For Additional Information Please Contact: Adaku Nwachukwu J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301 435-5560
Email: madua@mail.nih.gov
Fax: 301 402-0220
